首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

2112618

臨床蛋白質體學市場：技術、應用領域及至2030年的預測

The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030

出版日期: 2026年08月19日 | 出版商:

Kalorama Information | 英文 105 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

Kalorama Information 的「臨床蛋白質組學市場——技術、應用領域及 2030 年預測」分析了應用於臨床和製藥領域的蛋白質組學技術市場，特別關注下一代平台——儀器、耗材和試劑組，這些平台能夠在臨床研究中進行系統和多方面的蛋白質測量，在臨床試驗中進行生物標記分析，以及越來越重要的患者診斷。

本報告探討了該領域的一項根本性挑戰。目前，與「臨床」蛋白質體學相關的大部分收入來自研發，而非診斷檢測。儘管系統化的多層蛋白質分析平台已被廣泛用於生物標記發現、臨床試驗分層和人群規模研究，但只有少數應用（主要集中在神經病學、特定癌症和腫瘤分診領域）真正進入了臨床實踐。本報告追蹤了塑造這一領域格局變化的科技、企業和商業性趨勢。

本報告涵蓋了塑造該領域的關鍵測量技術——質譜、高多重親和性及結合劑檢測、超靈敏數位免疫檢測、空間蛋白質組學和單細胞蛋白質組學，以及新興的單分子蛋白質定序技術——以及支撐這些技術的富集、分離和樣品製備技術。報告也探討了影響市場的關鍵結構性趨勢，包括蛋白質體學公司持續融入大型儀器和診斷平台、親和性檢測向定序和PCR基礎設施的轉移、LDT/CLIA監管途徑在臨床商業化中的作用，以及儀器銷售和服務收入之間不斷變化的平衡。

「臨床蛋白質體學市場—技術、應用及至 2030 年的預測」提供了截至 2025 年按技術和地區分類的市場規模估計數據、蛋白質組學價值鏈上各公司的概況，以及對近期產品發布、監管批准和併購趨勢的回顧，這些都影響著競爭格局。

調查方法

「臨床蛋白質體學市場－技術、應用領域及2030年預測」報告重點在於與臨床研究中使用的系統性或多蛋白分析技術相關的儀器、耗材、試劑/試劑盒的收入，以及臨床試驗中的生物標記檢測和臨床診斷。報告也提及了合約研究和臨床實驗室服務，但為了避免重複累計已包含在產品銷售中的收入，這些收入未計入主要收入預測。本報告的研究是基於一手訪談、公司財務資訊披露、產品資料、會議論文集以及學術期刊和產業期刊的審查。

針對企業主管和大型公司的調查。

「臨床蛋白質體學市場—技術、應用領域及至 2030 年的預測」旨在為從事或評估臨床蛋白質體學領域的管理人員、策略和業務發展團隊、投資者、檢查室和製藥行業的生物標記領導者以及行銷專業人士提供參考。

Kalorama Information’s The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030 examines the market for proteomics technologies as applied to clinical and pharmaceutical settings, with particular attention to next-generation platforms - the instruments, consumables, and reagent kits that enable systematic, multiplexed protein measurement for clinical research, trial biomarker work, and, increasingly, patient diagnostics.

The report addresses a central tension in this field: most revenue currently associated with “clinical” proteomics comes from research and pharmaceutical development rather than diagnostic testing. Systematic and multiplex protein analysis platforms are widely used in biomarker discovery, trial stratification, and population-scale studies, while a smaller number of applications - concentrated in neurology, certain cancers, and oncology triage - have reached actual clinical use. The report tracks the technologies, companies, and commercial developments defining how that landscape is evolving.

Coverage includes the major measurement approaches shaping the field - mass spectrometry, high-plex affinity and binder-based assays, ultrasensitive digital immunoassays, spatial and single-cell proteomics, and emerging single-molecule protein sequencing - along with the enrichment, separation, and sample-preparation technologies that support them. The report discusses key structural trends affecting the market, including the ongoing consolidation of proteomics companies into larger instrument and diagnostics platforms, the migration of affinity-based assays onto sequencing and PCR infrastructure, the role of the LDT/CLIA regulatory pathway in clinical commercialization, and the shifting balance between instrument sales and services-based revenue.

The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030 provides estimated market size data segmented by technology and region for 2025, profiles of companies active across the proteomics value chain, and a review of recent product introductions, regulatory approvals, and deal activity shaping the competitive environment.

Scope and methodology

The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030 focuses on instrument, consumable, and reagent/kit revenue associated with systematic or multiplexed protein analysis technologies used in clinical research, clinical trial biomarker measurement, and clinical diagnostics. Contract research and clinical laboratory testing services are discussed but are not included in the core revenue estimates, in part to avoid double-counting revenue already reflected in product sales. Research for this report draws on primary interviews, company financial disclosures, product literature, conference proceedings, and journal and trade publication review.

Research Designed for C-Suite Executives, Key Companies, and More

The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030 is intended for executives, strategy and business development teams, investors, laboratory and pharmaceutical biomarker leaders, and marketing professionals working in or evaluating the clinical proteomics space.

CHAPTER 1: EXECUTIVE SUMMARY

ABOUT KALORAMA INFORMATION

INTRODUCTION

Overview

Trends Affecting the Market

SIZE OF MARKET

Table 1-1: Proteomics Clinical Applications Market Revenues, 2025-2030 (US$ millions)
Figure 1-1: Proteomics Clinical Applications Market Revenues, 2025-2030 (US$ millions)
Figure 1-2: Proteomics Clinical Applications Annual Market Growth, 2025-2030 (%)

SCOPE AND METHODOLOGY

CHAPTER 2: TECHNOLOGIES AND PRODUCTS

INTRODUCTION

TECHNOLOGIES USED IN CLINICAL APPLICATIONS OF PROTEOMICS

Mass Spectrometry

High-Plex Capable Affinity Techniques

Spatial Proteomics

Mass Cytometry

Automated and Capillary Western

Single-Molecule Protein Sequencing

PRODUCTS OFFERED IN CLINICAL PROTEOMICS AREAS

Analysis / Detection Platforms

Table 2-1: Selected Analysis and Detection Technologies in Clinical Proteomics

Mass Spectrometry Based Technologies

Table 2-2: Selected Mass Spectrometry Technologies in Clinical Proteomics

Affinity and Binder Based Techniques

Table 2-3: Selected Affinity and Binder Based Techniques in Clinical Proteomics

Enrichment, Separation, Sample Preparation

Table 2-4: Selected Enrichment, Separation, Sample Preparation Products and Technologies

Spatial Proteomics and Imaging Techniques

Table 2-5: Selected Spatial Proteomics and Imaging Techniques in Clinical Proteomics

Software and Informatics

Table 2-6: Selected Software and Informatics in Clinical Proteomics

Clinical Diagnostic and Biomarker Tests

Table 2-7: Selected Diagnostic Tests in or Related to Clinical Proteomics

Services and Contract Research

Table 2-8: Selected Services in Clinical Proteomics

CHAPTER 3: TRENDS

INTRODUCTION

Consolidation as Larger Companies Focus Strategy

Detection Methods Competing, Some Converging

Sequencing Infrastructure Applied as Proteomics Readout

Dynamic Range and Sensitivity Are Battleground

Cost and Throughput Unlocking Population-Scale Proteomics

Neurology Emerges as Beachhead Clinical Application

Oncology Broadening From Detection

Commercialization Often Using LDT/CLIA Model

Spatial and Single-Cell Proteomics on Frontier

Capital Markets Soft, Services and Pharma Steadier Ground

Evolving Technologies and Adjacent Products

RECENT PRODUCT INTRODUCTIONS AND REGULATORY APPROVALS

Table 3-1: Recent Product / Service Announcements, 2021-2026
Table 3-2: Regulatory Approvals and Related Announcements, 2021-2026

DEALS, COLLABORATIONS, ACQUISITIONS

Table 3-3: Deals, Collaborations, Acquisitions in Clinical Applications of Proteomics

CHAPTER 4: MARKET ESTIMATE AND FORECAST

INTRODUCTION

MARKET SIZE AND FORECAST BY SEGMENT

Table 4-1: Proteomics Clinical Applications Market Revenues, 2025-2030 (US$ millions)
Figure 4-1: Proteomics Clinical Applications Market Revenue Build, 2025-2030 (US$ millions)

MARKET SIZE BY REGION

Table 4-2: Proteomics Clinical Applications Market, by Region, 2025 (US$ millions)
Figure 4-2: Proteomics Clinical Applications Market, by Region, 2025 (US$ millions)
Figure 4-3: Proteomics Clinical Applications Market Share, by Region, 2025 (%)

MARKET SIZE BY TECHNOLOGY

Table 4-3: Proteomics Clinical Applications Market, by Technology, 2025 (US$ millions) [Affinity-based, MS-based, Ultrasensitive digital immunoassay, Other]
Figure 4-4: Proteomics Clinical Applications Market, by Technology, 2025 (US$ millions) [Affinity-based, MS-based, Ultrasensitive digital immunoassay, Other]
Figure 4-5: Proteomics Clinical Applications Market Share, by Technology, 2025 (%) [Affinity-based, MS-based, Ultrasensitive digital immunoassay, Other]